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only restorative treatment for patients is 
transplantation, which is limited by the 
availability of donor hearts and transplant 
rejection.[2,3] Even in cases where there 
is not critical RV dysfunction, RV output 
remains reduced, leading to poor quality 
of life.
Reparative therapies for improve-
ment of cardiac function are critical, and 
although limited in pediatric populations, 
new treatments are being explored.[4–9] 
While there have been hundreds of stem 
cell trials in adults, very few address 
pediatric populations.[4–6] A recent study 
showed that intracoronary infusion of 
cardiosphere-derived cells can improve RV 
function in children and follow-up studies 
have been promising.[7] In addition, bone 
marrow stem cells and cord blood-derived 
mononuclear cells also improved RV func-
tion following intramyocardial injection.[8] 
We have recently shown that progenitor 
cells (CPCs) could improve the failing 
RV of juvenile rats subjected to pulmo-
nary banding and a clinical trial is now 
underway (NCT03406884).[9] Despite this 
enthusiasm, similar concerns exist in children as have been 
shown in adults. While CPC therapy demonstrated modest 
improvements in adult therapy, most CPCs were lost to circu-
lation immediately after injection into the myocardium.[10,11] 
In addition, cells are being injected into a diseased micro-
environment that may not provide healthy cues for optimal 
CPC function.[11]
To increase retention and modify the local microenviron-
ment, researchers have used both synthetic and natural bioma-
terials.[12,13] Inclusion of appropriate cues can both direct the 
fate of the implanted cells, and improve the release of parac-
rine factors, a main mechanism of cellular therapy.[14,15] Several 
studies, including ones from our laboratory, have shown that 
a decellularized cardiac extracellular matrix hydrogel (cECM) is 
a promising biomaterial used in the repair of myocardial dys-
function in adults, as well as for the delivery of stem cells.[16–21]  
In prior studies, cECM increased the differentiation of rat 
CPCs compared to either collagen or adipose ECM alone.[16,20] 
Moreover, cECM is currently in clinical trials for adults post-
myocardial infarction (NCT02305602) and thus, combined 
with human pediatric CPCs, could rapidly advance to human 
testing. In adults, the material is delivered invasively through 
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Cardiac Bioprinting
1. Introduction
Congenital heart defects affect 35 000 newborns annually, 
resulting in significant impairments in cardiac function and 
increased patient morbidity and mortality.[1,2] Although surgical 
treatment methods have improved outcomes, many children 
end up with right-ventricular (RV) dysfunction due to increased 
load.[1,2] This chronically elevated load leads to increased fibrosis 
and hypertrophy, resulting in RV failure.[1] In cases where RV 
dysfunction persists, 18-month survival rates are 35%.[3] The 
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a catheter, which can present certain challenges.[19] For one, 
the local structure of the material cannot be controlled during 
injection, a property that may alter stem cell phenotype.[22] In 
addition, while myocardial infarction is a localized disease, 
heart failure due to congenital heart defects may be more global 
and local delivery may not be sufficient.[1–3]
One powerful method of generating controlled 3D struc-
tures for cardiac therapy is bioprinting, which has been 
used extensively to produce highly defined geometries of 
biomaterials and cells.[23–28] Bioprinting is effective in gen-
erating polymeric scaffolds, but can be problematic for 
naturally derived materials.[24,25] For the case of bioprinting 
ECM-derived materials, current methods rely on creating 
nondegradable polymeric support scaffolds, or require high 
concentrations of poorly printed ECM.[26–28] The inclu-
sion of polymers produces device-tissue and cell-material 
mechanical mismatch, and imposes degradation limita-
tions.[29] Further, finding materials that are compatible with 
ECM printing is not trivial.[30,31] A bioprinting methodology 
that prints both cells and ECM without using nondegradable 
components is key in generating functional heart patches 
with high design control.
This work focuses on developing a bioprinted cardiac patch 
composed of native cECM and pediatric human CPCs (hCPCs), 
for use as an epicardial device that releases paracrine factors 
into the dysfunctional myocardium. The patch may overcome 
problems seen in cell therapies by retaining viable hCPCs in 
naturally derived cECM, and allowing for improved paracrine 
release from hCPCs through the bioactive cECM inducing 
guiding effects on cells.[10,16,20] Additionally, the bioprinting 
approach allows for generation of highly defined patches with 
uniform component distribution.[23] Ultimately, the patch 
could be used as therapy for pediatric patients suffering from 
RV failure, or perhaps even in an allogeneic manner for adult 
cardiac dysfunction.
2. Results and Discussion
2.1. Bioprinting of hCPC/cECM Cardiac Patches
2.1.1. Bioprinting Acellular Structures
Bioprinting of ECM-based materials has mainly been achieved 
with the inclusion of a filler polymer to allow for proper 
printing viscosity.[23,25,26] ECM solutions at therapeutic concen-
trations (6–10 mg mL−1) are low viscosity prepolymers, which 
do not print effectively due to layers remaining fluid and nono-
verlapping, while polymerized ECM is a fibrous material that, 
while more viscous then the prepolymer, comes out in “chunks” 
rather than a homogenous stream of print filaments.[18,19,26] 
Surprisingly, cECM has been printed directly without the use 
of filler polymer; however, this approach suffers from two main 
issues.[26,32] The first is that the required concentration for 
printing pure cECM (20 mg mL−1) is significantly higher than 
has been used in treatment studies with cECM and requires 
extensive harvesting from porcine sources for generation of a 
limited number of devices. Second, and more pressing, is that 
the pure cECM-printed materials are difficult to handle and 
risk rupture when potentially used as an epicardial patch, due 
to their low mechanical modulus and fibrous nature.[18,33] In 
order to address this, cECM was printed with the use of filler 
polymers such as polycaprolactone in alternating layers, which 
then produced mechanical mismatch with the patch and the 
native myocardium, also rendering the patch with a degrada-
tion time much longer than a natural biomaterial system.[32] 
Although methods have been employed to modify pure cECM 
mechanical properties in printed constructs, such as by inclu-
sion of vitamin B2, it is unclear if this method can be employed 
as a cell-laden patch without the use of supporting polymer 
layers.[27,32]
To generate a cECM patch that has a high degree of printa-
bility, proper mechanical properties for myocardial therapy, and 
allows for cell viability and paracrine release, we used gelatin 
methacrylate (GelMA) as a support material. GelMA is a natural 
biomaterial based on collagen, which has methacrylate groups 
grafted onto the gelatin structure so that the material can 
undergo radical polymerization.[34,35] GelMA is used extensively 
as a bioactive and resorbable material for regenerative medicine 
applications, and in a multitude of tissues such as muscle, liver, 
and bone.[34–36] In order to limit cell damage, we employed a 
white light system for gel polymerization after structure forma-
tion. This white light system has advantages over UV systems 
that otherwise induce increased cell death and stress.[37–39] We 
investigated the use of various cross-linking systems, such as 
ruthenium-sodium persulfate or Irgacure 2959, but found that 
an Eosin Y system allowed for the most effective formation of 
structurally reliant and viable patches.[35,38,39] Most importantly 
for bioprinting, GelMA undergoes a polymerization when 
cooled from physiological temperatures to below 10 °C, and is 
viscous even at room temperature with concentrations of 10% 
weight/volume (w/v) and above. This phase transition makes 
it suitable for bioprinting as a natural material, and has been 
used often for this application.[39] This work utilized 5% w/v 
GelMA in the bioink formulations so that the bioink was still a 
significant portion cECM (8 mg mL−1), compared to increasing 
the concentration of GelMA to 10% or higher, which would 
have produced a bioink that is mostly GelMA with some cECM 
added. In addition, low w/v % GelMA supports more effective 
cellular outcomes such as viability and proliferation.[40] Our 
printing strategy involved cooling 5% w/v GelMA to 10 °C for 
10 min to allow for gelation and enhanced printing viscosity of 
the cECM/hCPC bioink. An overview of the printing strategy is 
seen in Figure 1.
The printing methodology allowed for clean and defined 
extruded filaments when printing either GelMA or GelMA-
cECM (Figure 2A). To ensure that the cECM fibers were uni-
formly distributed in the printed structures, we stained the 
cECM with AF568, which forms a strong bond to primary 
amines on the cECM proteins. The red staining in Figure 2B 
is the cECM fibers, indicating that the cECM was distributed 
homogeneously throughout the entire printed structure, rather 
than in clumped locations such as filament junctions. A higher 
magnification in 3D of a printed filament in Figure 2C shows 
that the cECM formed homogeneously distributed dense fibers 
after polymerization at physiological pH and temperature. We 
quantified the printability of the structures using a parameter 
based on the extent to which the holes between filaments 
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match a square shape, as previously described and discussed in 
the Experimental Section.[41] A value of printability close to 1.0 
demonstrates ideal gelation, and thus the printing property, of 
the bioink. This value shows that the holes are close to a perfect 
square shape due to the filaments being uniform in thickness, 
homogeneous, and rigidly defined with multiple layers stacking 
on one another. As can be seen in Figure 2D, both GelMA 
and GelMA-cECM bioinks had printability close to a value of 
1.0 and the inclusion of cECM improved the printability of the 
bioink significantly to achieve a value closest to ideal printing.
2.1.2. Bioprinting hCPC-Laden Structures and Cardiac Patches
Following incorporation of cECM in to the printed structure, 
we next sought to determine if primary cells could be added 
to the printing mix. To perform this, hCPCs were incorporated 
into the bioinks and evaluated for effectiveness in creating 
homogeneously distributed cell-laden print structures. Nonex-
trusion-based bioprinting methods require high printing pres-
sures that render cells nonviable or methodologies that result 
in dispersion of cells toward the edges of printed constructs, 
rather than homogeneously distributed throughout.[42,43] In 
addition, cells can leach out of printed hydrogel constructs 
if the materials are soft and not effectively polymerized, 
resulting in a loose network.[44] As shown in the bright field 
images in Figure 3, we were able to add cells to the print for 
both GelMA alone (Figure 3A) and GelMA-
cECM (Figure 3B), where cells were retained 
in the gels after cross-linking. To obtain a 
clearer image of hCPCs throughout the test 
grids, cells were stained with a lipophilic dye 
(DiD) prior to printing. Figure 3C shows the 
printed grids after swelling, indicating that 
the cells appeared homogeneously distrib-
uted throughout the filaments. To quantify 
distribution, an averaged fluorescence line 
scan along filaments showed that the fluo-
rescence intensity throughout the filaments 
was uniform and that the cells were homo-
geneously distributed (Figure 3D). Cells were 
incorporated throughout the filaments, and 
GelMA-cECM grids once again appeared 
to have better printability, as indicated by 
the hole geometry, where the GelMA-cECM 
grids had more square holes than GelMA 
grids. Printing parameters were not modified 
by the incorporation of cells, maintaining a 
low printing pressure (0.7–0.8 bar), and thus 
low shear stress, on the cells. In addition, 
cells remained firmly supported within the 
printed constructs, with no cells leaching out 
of the grids or sifting to the bottom of the 
filaments.
The hCPC/cECM bioink was shown 
to have ideal printability with homoge-
neous distribution of both cECM and 
hCPCs throughout the printed structures, 
as described in the above sections. Moving 
on, we were able to create cardiac patches using the cell-laden 
bioink, based on a cylindrical shape, as indicated in Figure 4. 
Figure 4A shows the printed patches prior to white light poly-
merization while Figure 4B shows the CAD models using the 
patch design. The patches were pink due to the Eosin Y photo-
initiator and change to clear after polymerization. The printed 
patches maintained the same shape and structure as the CAD 
model, due to the high printability bioink. The infill pattern of 
the patches were perpendicular aligned filaments generated 
through multiple print layers, indicating further degrees of 
printing control and structure fidelity.
2.2. hCPC Viability, Differentiation, and Proliferation  
within Bioprinted Cardiac Patches
Evaluating the viability of cells within the cardiac patches is 
critical to ensure live cells that can participate in producing 
important proreparative paracrine factors.[12,15] Evaluation of 
cell viability directly is also critical within bioprinted scaffolds, 
particularly because bioprinting has been shown to reduce cell 
viability in printed constructs due to high shear stresses on the 
cells from small diameter needle tips, such as the tips used in 
this study.[42,43] In addition, cells grown in thick 3D structures 
can suffer death due to lack of nutrient diffusion, particularly 
at the center of the structures, producing a necrotic core.[42,45] 
As shown in Figure 5, hCPCs within printed cardiac patches 
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Figure 1. Printing overview. A) Bioink preparation involved combining cECM, hCPCs, and 
GelMA to form naturally derived and cell-laden materials for printing. B) Printing methodology 
involved cooling the bioink to 10 °C in the 3D bioprinter barrels to allow GelMA polymeriza-
tion for improved printability. Patches were printed with infill patterns of 90° intersecting fila-
ments and contour. Patches were polymerized via white light to induce radical polymerization 
of GelMA, followed by incubation at 37 °C for at least 1 h to induce cECM polymerization. 
C) Patch implementation will involve pericardially inserting the patch to the RV of pediatric 
patients, where the patch will release key proregenerative paracrine factors.
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were stained to determine the total number of dead (red) to 
live (green) cells for either GelMA (Figure 5A) or GelMA-cECM 
(Figure 5B). Cell viability was quantified by measuring the 
number of live and dead cells at different locations and heights 
within the cardiac patch at days 1, 3, and 6 after formation and 
showed high viability, from 70 to 80% live cells on average 
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Figure 3. Printing hCPC-containing bioinks. A) Bright-field image of printed test grids of GelMA bioinks containing hCPCs, taken 1 h after printing. B) Bright-
field image of printed test grids of GelMA-cECM bioinks containing hCPCs. C) Fluorescence image of printed test grids of GelMA-cECM with hCPCs stained 
with DiD. D) Normalized fluorescence intensity of line scans performed on stained hCPC test grids. Line scans were performed across several filaments.
Figure 2. Printability analysis of GelMA-cECM bioinks. A) Bright-field image of printed test grids of GelMA. B) Fluorescence image of printed test grids 
of GelMA-cECM with staining for cECM by AF568. C) 3D fluorescence close-up view of printed filament of GelMA-cECM, with staining for cECM by 
AF568. D) Printability comparison between GelMA and GelMA-cECM bioinks. * = p-value < 0.03, given by paired t-test, n = 5.
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Figure 4. Printed patches. A) Printed patches of 10 mm diameter and 0.6 mm height. Patches are printed uniformly from patch to patch, and the 
grid infill pattern can be seen. Patches are pink postprinting due to inclusion of photoinitiator Eosin Y, and become clear postpolymerization. B) CAD 
model sketch used for patch printing.
Figure 5. hCPC functionality within printed patches. A) Characteristic live/dead fluorescence image of hCPCs in GelMA patches, with live cells marked 
green (Calcien AM) and dead cells marked red (EtD) at 1 d after formation. B) Characteristic live/dead fluorescence image of hCPCs in GelMA-cECM 
patches at 1 d after formation. C) Viability of hCPCs in printed patches at 1, 3, and 6 d. D) Proliferation of hCPCs in printed patches at 3 and 7 d, where 
absorbance intensity is normalized to the measured absorbance of hCPCs in GelMA patches in all experiments. E) Fold change gene expression over 
hCPCs in GelMA patches for Cx43, GATA4, MEF2C, MYH7, VE-Cad, CD31, FLT-1, and ACTA-2 at day 3. F) Fold change gene expression over hCPCs in 
GelMA patches for Cx43, GATA4, MEF2C, MYH7, VE-Cad, CD31, FLT-1, and ACTA-2 at day 7. * = p-value < 0.05, ** = p-value < 0.005, given by ANOVA 
with Tukey’s post-test, n = 3–6 for all samples at all time points.
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seen in Figure 5C. There was no significant difference between 
groups or time points when comparing the percent of viable 
cells. Throughout all structures, there was no necrotic core or 
reduction of cell viability, indicating that nutrient diffusion 
was likely not a factor. The cell viability overall was most likely 
not impacted significantly by the printing methodology, or if 
there were effects to the cells due to the printing, the degree 
of cell damage was mitigated by the material being an effec-
tive environment for cell growth and nutrient diffusion coupled 
with printing of aligned fibers which may be beneficial to cell 
function.
Proliferation and differentiation are additional parameters 
that are important in characterizing functionality of hCPCs in 
bioprinted patches. hCPC-laden patches were grown in cul-
ture media supplemented with EdU for 3 and 7 d, and absorb-
ance intensity from GelMA-cECM patches was normalized 
to values measured from GelMA patches. While there was no 
difference between the proliferation of hCPCs in GelMA and 
GelMA-cECM patches after 3 d, as seen in Figure 5D, hCPCs 
in GelMA-cECM patches had reduced proliferation compared to 
GelMA patches after 7 d. Similarly, hCPC-laden patches were 
grown for 3 and 7 d, and the fold change in genetic expression 
of key cardiac, endothelial, and smooth muscle genes from 
hCPCs in GelMA-cECM patches compared to hCPCs in GelMA 
patches was assessed through polymerase chain reaction (PCR). 
Analysis of gene expression of cardiac transcription factors 
GATA4 and myocyte enhancement factor 2C (MEF2C) and car-
diac-specific proteins connexin 43 (Cx43) and β-myosin heavy 
chain (MYH7), endothelial cell markers vascular endothelial 
cadherin (VE-Cad), platelet endothelial cell adhesion molecule 
(CD31), and vascular endothelial growth factor receptor 
1 (FLT-1), and smooth muscle marker α-smooth muscle actin 
(ACTA-2) was evaluated at 3 and 7 days, as seen in Figure 5E,F. 
hCPCs in GelMA-cECM patches showed enhanced cardiac dif-
ferentiation through increased expression of MEF2C, Cx43, 
and MYH7, and decreased expression of GATA4, an early dif-
ferentiation marker, indicating that the hCPCs in GelMA-cECM 
patches were moving toward later differentiation than hCPCs in 
GelMA patches. hCPCs in GelMA-cECM patches also showed 
increased expression of endothelial marker CD31 at day 3, 
although there was no difference in expression of endothelial 
markers VE-Cad and FLT-1 or smooth muscle marker ACTA-2. 
At day 7, expression of all cardiac and endothelial markers was 
increased in GelMA-cECM patches, with higher fold-change 
values than day 3. ACTA-2 remained unchanged between 
groups at both days. Thus, we conclude that incorporation of 
cECM into patches improved both cardiac and endothelial dif-
ferentiation of hCPCs, while not influencing smooth muscle 
differentiation. The enhanced differentiation of hCPCs in 
cECM incorporated patches at day 7 mirrors the prolifera-
tion trends seen in Figure 5D, as stem cells most often show 
reduced proliferation with increased committed. These assess-
ments also reaffirm the results measured for hCPCs in 2D cul-
ture, where cECM improved differentiation of CPCs compared 
to cells grown on collagen-based materials.[16] Regardless, it is 
clear that while hCPCs remained viable in printed patches, the 
inclusion of cECM improved differentiation and reduced prolif-
eration of hCPCs, which in turn may improve paracrine poten-
tial of hCPC-laden GelMA-cECM patches.
2.3. Proangiogenic Potential of hCPC/cECM Cardiac Patches
Many studies now attribute the true benefit of cell therapy to 
be release of paracrine factors.[15,46–50] To evaluate paracrine 
release, we grew cell-laden patches in treatment media for 
up to 7 d and collected the conditioned media every 2 d. We 
then performed a tube formation assay using human umbilical 
vein endothelial cells (HUVECs) cultured on Matrigel with 
conditioned media. HUVECs grown in either nonconditioned 
treatment media or endothelial cell growth media with sup-
plemented growth factors showed similar values for total tube 
length formed, so nonconditioned treatment media was used 
as positive controls. As shown in Figure 6, HUVECs formed 
tube-like structures when cultured in conditioned media taken 
from both cell-laden GelMA (Figure 6A) and GelMA-cECM 
(Figure 6B) patches. When comparing the angiogenic potential 
of cell-free patches, seen in Figure 6C, there was no difference 
between GelMA and GelMA-cECM groups. In contrast, the 
angiogenic potential of media collected from cell-laden GelMA-
cECM patches was significantly higher than media from GelMA 
patches alone at day 3, while both groups showed improved 
angiogenic potential at day 7 compared to day 3. While GelMA-
cECM was superior at both time points, both groups showed 
an increase in angiogenic potential over time. While there 
are many other parameters that conditioned media may alter, 
angiogenesis may be one of the most important for improving 
cardiac function. Additionally, we may be underestimating the 
effects as some growth factors released may interact with the 
GelMA and/or cECM and prevent release into the conditioned 
media, as studies have shown that growth factors, such as hep-
arin binding growth factor and hepatocyte growth factor, bind 
to cECM and are released gradually.[51,52]
In developing effective hydrogels for soluble factor release, 
it is key to generate materials that are stiff enough to allow for 
scaffold stability, but do not have too dense a network that limits 
cellular functions and release of signaling factors.[44] Systems 
that balance these parameters have been developed around 
natural or synthetic materials, many of which prove effective 
in releasing reparative factors into damaged tissues, whether 
through encapsulation of regenerative cells or the factors them-
selves.[46–49] The hCPC-laden GelMA-cECM patches developed 
here also allowed for generation of a solid patch with enhanced 
factor release. These results are similar to other materials that 
have been developed, but with incorporation of cardiac specific 
cells and matrix that may release cardiac-specific paracrine fac-
tors. This cardiac specificity in the patch design may be most 
beneficial in repairing the damaged myocardium, as opposed 
to using non-tissue-specific biomaterials such as GelMA.[19,46,50]
2.4. Mechanical Characterization of Bioprinted Patches
Mechanical properties of biomaterials play a critical role in 
modulating cellular function. Stem cells are more viable, pro-
liferative, and produce more effective regenerative outcomes 
when grown in hydrogels that match the properties of native 
tissue.[12,53] This is also true as well for hCPCs, where cells per-
form more effectively when grown in materials that match the 
mechanical modulus of native myocardium from 5 to 15 kPa.[54] 
Adv. Healthcare Mater. 2018, 7, 1800672
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A material modulus that more closely matches the myocardium 
also ensures there is limited mechanical mismatch between 
the hydrogel and the heart, which can otherwise cause prob-
lems such as dissection, buckling, or immune responses.[29,55] 
While GelMA and GelMA-cECM patches are evaluated in this 
study, we also evaluated the use of modifying the mechanical 
properties of the patches by adding acrylate groups using 
N-succinimidyl acrylate, as employed in previous studies.[33] 
While the modification increased stiffness over GelMA and 
GelMA-cECM groups, the patches more readily degraded com-
pared to both groups and did not alter the hCPC viability or 
paracrine function over GelMA-cECM (data not shown), so this 
direction was not pursued further, although the properties of 
the patch could potentially be modified through this method.
As seen in Figure 7A, the modulus of pure GelMA was 
3000 Pa, similar to published studies, though short of the 
native myocardium.[56] Incorporation of cECM significantly 
increased the modulus to 5000 Pa, indicating that the material 
properties of the GelMA-cECM patch could be tailored within 
physiological ranges. In addition to stiffness, we also meas-
ured swelling ratio in Figure 7B. All samples were sufficiently 
hydrated, with a swelling ratio between 9 and 12. There was a 
decrease in the swelling ratio between the GelMA and GelMA-
cECM groups, which was expected as increases in stiffness 
suggest a tighter polymer network and result in more liquid 
exclusion.
As a cardiac patch must persist for the repair process, deg-
radation time is a critical parameter. We evaluated the degra-
dation of patches and materials in cell treatment media over 
21 d by examining both the change in wet weight (Figure 7C) 
and change in stiffness (Figure 7D). When comparing weight 
change of printed patches or the change in stiffness of the 
materials, both groups remained solid and did not signifi-
cantly degrade over the range of 21 d. Although the data pre-
sented describe the degradation of patches without cells, 
patches that incorporated cells lasted the duration of testing 
shown in Sections 2.3 and 2.4 with no observable degrada-
tion. It is important to describe this method of degradation as 
only evaluating hydrolysis, as opposed to exposing the patch 
to conditions seen in vivo including proteases, cyclic strain, 
and shear stresses. To evaluate the degradation of the patches 
in a more physiological relevant environment, hCPC-laden 
materials were cultured in conditioned media harvested from 
cardiac fibroblasts (cFBs), which would be present in cases of 
ventricular remodeling and hypertrophy. The cFB conditioned 
media more closely captures the environment of patches in 
vivo due to incorporation of a complex mixture of remodeling 
components, compared to commonly employed incubation 
in collagenase I, which degrades the patches in a matter of 
hours and may not be as physiologically relevant. As seen in 
Figure 7E, hCPC-laden GelMA materials did not degrade or 
change mechanical modulus over the course of 7 and 21 d 
in cFB conditioned media. Interestingly, while hCPC-laden 
GelMA-cECM materials did not degrade or change mechanical 
modulus over the course of 7 d, by 21 d the material stiffness 
increased compared to the stiffness at both 1 and 7 d. The 
change in stiffness at 21 d is also significantly higher than 
hCPC-laden GelMA materials at the same time and may be 
due to stimulation of the hCPCs to remodel their environment. 
Regardless, the GelMA-cECM patches, both with and without 
hCPCs, do not degrade in vitro over an extended timeframe 
and may be suitable for extended retention in vivo.
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Figure 6. Angiogenic potential of cardiac patches. A,B) Characteristic HUVEC tube formation after 6 h when grown with conditioned media collected 
at day 7 from cell-laden GelMA and GelMA-cECM patches. C,D) Total HUVEC tube length normalized to positive controls for cell-free and cell-laden 
patches. * = p-value < 0.05, given by ANOVA with Tukey’s post-test, n = 3–6 for all samples at all time points.
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2.5. In Vivo Implantation of GelMA-cECM Patches
Attachment of GelMA-cECM patches onto the epicardial sur-
face is critical to ensure the devices can be deployed with min-
imal manipulation. We evaluated the potential of the patches 
to remain attached to rat hearts after placement on the epicar-
dium. As can be seen in Videos S1 and S2 (Supporting Infor-
mation), surgical attachment of the patches was achieved on 
rat hearts via placement on top of the epicardial surface of the 
right ventricle after opening the chest cavity and exposing the 
beating heart. Three methods of attachment were evaluated—
simple placement on the epicardium without secondary sup-
port, placement on the epicardium followed by covering with 
the pericardium, and placement on the epicardium with a 
single suture. All three methods allowed for patch placement 
on beating rat hearts, without buckling or patch damage. Prior 
to patch generation, cECM was incubated with a fluorescent 
dye for postimplantation imaging. The simple placement 
without secondary support resulted in patch movement, indi-
cating that some sort of support was needed for patch reten-
tion. Following the pericardial and suturing methods, hearts 
were excised from rats and fluorescently imaged to determine 
if the patch remained on the heart. Of eight patches implanted, 
all were retained up to 7 and 14 d, regardless of pericardial or 
suturing attachment method. As seen in Figure 8, patches were 
retained at day 7 (Figure 8A suture), and day 14 (Figure 8B 
pericardial, Figure 8C suture) with clear and stable fluores-
cent signal up to 14 d. Both methods did not require the use 
of surgical adhesive such as fibrin, which may impose a barrier 
layer for paracrine release.[57] However, the pericardial method 
required cutting of the patches into smaller than 10 mm sizes 
before placement in two out of the three animals evaluated with 
this method, as the full patch tended to fold upon covering 
with the pericardium, indicating that the suturing method 
Adv. Healthcare Mater. 2018, 7, 1800672
Figure 7. Material analysis of printed patches. A) Viscoelastic storage moduli of GelMA and GelMA-cECM. B) Swelling ratio of GelMA and GelMA-
cECM patches. C) Degradation of patches, measured as the sample weight compared to initial weight of the patches postswelling. D) Degradation 
of cell-free materials in cell culture media, measured as the sample storage modulus compared to the initial modulus of the material postswelling. 
E) Remodeling of hCPC-laden materials grown in cFB conditioned media, measured as the sample storage modulus compared to the initial modulus 
of the material postswelling. * = p-value < 0.05, ** = p-value < 0.01, *** = p-value < 0.005, given by ANOVA with Tukey’s post-test, n = 3 for all samples 
in all subfigures.
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may be ideal for implementing a large device. In either case, 
the patches were retained throughout 14 d without change to 
patch shape, fluorescence expression of the cECM-bound dye, 
or buckling. The rat heart beats ≈400–500 times min−1, signifi-
cantly more than the human heart and thus these results are 
quite promising. Interactions between the patches and myo-
cardium were evaluated using Isolectin staining for host vessel 
formation. As seen in Figure 8D, vessels were formed in the 
patches after 14 d in vivo, indicating that the patches integrate 
with the native myocardium and allow for nutrient delivery to 
the implanted cells. Overall, the patches were retained on the 
myocardium and became vascularized over the course of 14 d. 
While this study only sought to determine the feasibility of use, 
future studies will examine the efficacy of the patch in diseased 
animal models in greater detail.
3. Conclusions
Here, we report the development of a novel pediatric hCPC/
cECM cardiac patch that was generated through bioprinting. 
The inclusion of 5% w/v GelMA allowed for printability of 
the hCPC/cECM bioink through GelMA polymerization via 
cooling to 10 °C, followed by white light radical polymerization 
and incubation at physiological temperatures. The inclusion 
of cECM allowed for improved printability over pure GelMA 
bioinks, and the hCPC-laden GelMA-cECM bioinks showed 
homogeneous distribution of cells and matrix. This method-
ology can potentially be employed to generate cardiac patches 
that can be customized to the target patient tissue. hCPCs 
remained highly viable and proliferative within the patch up 
to 7 d and hCPCs in GelMA-cECM patches had improved dif-
ferentiation and angiogenic potential over pure GelMA patches, 
indicating their improved reparative functionality. The inclu-
sion of cECM resulted in patches with a mechanical modulus 
that was similar to that of native myocardium and all patches 
were sufficiently hydrated. Patches did not significantly degrade 
over 21 d when tested in vitro through weight change and rheo-
logical analysis. In addition, hCPC-laden GelMA-cECM patches 
showed increased stiffness over 21 d when cultured in cFB con-
ditioned media, indicating potential remodeling and retention 
in vivo. Finally, the printed GelMA-cECM patches were effec-
tively attached to rat hearts epicardially, remained on the hearts 
for 14 d, and showed vascularization.
The printing of native ECM is difficult to do at concentra-
tions that can be realistically used and support cell functions. 
The concentration of cECM used here is similar to previous 
studies performed in our laboratory and by others that sup-
port CPC differentiation and function. In addition, all mate-
rials used in this study are clinically relevant as both cECM and 
hCPCs are in clinical testing alone. Thus, the idea of a patient-
specific, 3D-printed patch is of great translational value. With 
printability achieved, future directions include incorporation of 
increased amounts of proregenerative ECM components such 
Adv. Healthcare Mater. 2018, 7, 1800672
Figure 8. In vivo patch retention. hCPC-laden GelMA-cECM patches (yellow) are retained after 7 d: A) suture method and 14 d; B) pericardial tucking 
method and C) suture method following implantation. D) Immunohistological analysis of vasculature formation (green) and cells (blue) after 14 d in 
vivo.
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as agrin, sulfated glycosaminoglycans, or periostin that may 
improve the paracrine factor release by inducing modulations 
in hCPC function for a bottom-up, modular approach to tissue 
engineering. Additionally, evaluation of other critical bioactive 
factors such as cellular exosome release and the extent of attach-
ment of the hCPCs within the patches may help evaluate how 
hCPCs are modified by inclusion of cECM and how the cellular 
changes effect paracrine release. Translation of the patch would 
involve the use to autologous hCPCs derived directly from 
patients, allowing for generation of patient-specific paracrine 
release while using commercially available biomaterials such as 
porcine cECM. Following hCPC expansion, patch manufacture 
can be expedited and customized through the 3D bioprinting 
methodology, which allows for incorporation of additional com-
mercially available cell sources such as mesenchymal stem 
cells, and the tailored patch can be delivered directly to the 
patient for surgical attachment. Most importantly, therapeutic 
directions include testing the patches in vivo on animal models 
of RV failure to evaluate cellular changes such as angiogenesis, 
fibrosis, and cardiomyocyte proliferation, as well as tissue level 
parameters such as ejection fraction and RV wall thickness.
4. Experimental Section
Materials: GelMA was purchased from CellINK (Gothenburg, 
Sweden). Triethanolamine (TEOA), 1-vinyl-2-pyrrolidione (NVP), HEPES 
sodium salt, bovine gelatin, Tiron X-100, sodium dodecyl sulfate, 
and pepsin were purchased from Sigma-Aldrich (MO, USA). Insulin-
transferrin-selenium (ITS) media, Hams F-12, Matrigel Matrix Growth 
Factor Reduced, Dulbecco’s modified Eagle medium (DMEM), and 
penicillin-streptomycin (Pen-Strep) were purchased from Corning Cellgro 
(NY, USA). Eosin Y sodium salt was purchased from TCI (MA, USA). 
Nordson EFD 30cc barrels, pistons, and 27-gauge plastic tips were 
purchased from TEK products (MN, USA). Standard fetal bovine serum 
(FBS) and RNase-free water were purchased from Hyclone (PA, USA). 
l-glutamine was purchased from MP Biomedicals (OH, USA). Cell 
culture dishes and well plates were purchased from Cellstar (PA, USA). 
Calcein AM, ethidium homodimer-1 (EtD), DAPI, Vybrant DiD cell 
solution (DiD), Dynal magnetic beads, Trizol, Power SYBR Green, first 
strand buffer, dithiothreitol, Click-iT EdU Microplate Assay, RNaseOUT 
Inhibitor, M-MLV, Alexa Fluor 568 Carboxylic acid Succinimidyl Ester 
(AF568), and Alexa Fluor 790 Carboxylic acid Succinimidyl Ester (AF790) 
were purchased from Invitrogen (CA, USA). Phosphate buffered saline 
(PBS) and hexamers were purchased from Fisher Scientific (NH, 
USA). Olido(dT) and dNTP were purchased from Fermentas (MA, 
USA). Primers were purchased from Integrated DNA Technologies 
(IL, USA). Fluorescein Griffonia Simplicifolia Lectin I Isolectin B4 
(IsolectinB4-FITC) was purchased from Vector labs (CA, USA). 
HUVECs were purchased from Lonza (Basal, Switzerland). Endothelial 
cell growth media kits (include growth factors) were purchased from 
R&D Systems (MN, USA). Hank’s balanced salt solution (HBSS) was 
purchased from Gibco (OK, USA). Collagenase type 2 (300 U mL−1) 
was purchased from Worthington (NJ, USA). Anti-c-kit H300 antibodies 
were purchased from Santa Cruz (TX, USA). Bovine fibroblast growth 
factor (bFGF) was purchased from Stem Cell Technologies (Vancouver, 
Canada). QIAshredder centrifuge filters were purchased from QIAGEN 
(Hilden, Germany). Sprague-Dawley rats were purchased from Charles 
River (MA, USA). Isoflurane was purchased from Piramal Healthcare 
(Mumbai, India). Prolene was purchased from Ethicon (NJ, USA).
Neonatal Human Cardiac Progenitor Cell Isolation and Culture: The 
institutional review board at Children’s Healthcare of Atlanta and Emory 
University approved the harvesting of human neonatal c-kit expressing 
hCPCs from atrial appendage, as previously described.[17,58] In short, 
right atrial appendage tissue was obtained from pediatric patients 
aged one week or less undergoing heart surgeries due to congenital 
heart diseases. The atrial appendage tissue was transported using 
Krebs-Ringer solution, washed with HBSS, and broken down into small 
sections. The tissue was then enzymatically degraded using 1 mg mL−1 
of collagenase type II at 37 °C, 5% CO2 for 30 min and passed through 
a 70 µm filter. The mixture was centrifuged at 1000 g for 5 min to pellet 
the cells. The cells were combined with magnetic beads conjugated 
with anti-c-kit antibody, allowed to incubate for 2 h at 37 °C, followed 
by magnetic sorting and successive washes with cell culture media. 
Separated c-kit+ cells were expanded and expression of c-kit in the cell 
population was measured by flow cytometry to ensure they were at least 
90% positive. Cells from three donors were pooled at first passage and 
used in all experiments described in this research. hCPCs were grown in 
T-75 cell culture treated dishes with culture media for expansion. Media 
was changed every 2–3 d until bioink preparation. Cell culture media 
consisted of Ham’s F-12 media supplemented with 1× Pen-Strep, 1% 
l-glutamine, 10% FBS, and 10 ng mL−1 bFGF.
Cardiac Extracellular Matrix Isolation and Characterization: 
Decellularized porcine ventricular extracellular matrix (cECM) was 
generated and processed as previously described.[17,16,33] Briefly, porcine 
ventricular tissue was separated, sectioned into small pieces, rinsed 
in PBS, and decellularized using a 1% solution of SDS for 4–5 d. The 
decellularized cECM was rinsed with water, frozen at −80 °C overnight, 
lyophilized, and milled into a fine powder. Then, the cECM was 
processed into liquid form by partial digestion with pepsin (1 mg mL−1) 
in 0.1 m HCl for 2 d, at a ratio of 10:1 of cECM to pepsin. The cECM was 
then raised to basic pH by adding 1 m NaOH and salt concentration 
of 1× PBS, followed by adjustment to pH of 7.4 using HCl and NaOH 
and diluted to a solution concentration of 8 mg mL−1. The solution was 
aliquoted, immediately frozen at −80 °C overnight, lyophilized for 24 h, 
and stored at −80 °C prior to use.
Rat Cardiac Fibroblast Isolation and Conditioned Media Harvesting: 
cFBs were isolated as previously described.[59] In short, hearts were 
excised from adult male rats, shredded, and subjected to digestion with 
1 mg mL−1 trypsin in HBSS at 4 °C for 6 h. The solutions were digested 
with 0.8 mg mL−1 collagenase in HBSS at 37 °C for 15 min and then 
quenched with cell culture media. The cell suspensions were passed 
through 100 µm filters, followed by cell pelleting and plating for 3 h to 
allow for cFB adherence, and then washed to remove non-cFBs. cFBs 
were grown in fibroblast growth media, which is composed of DMEM 
supplemented with 1× Pen-Strep, 1% l-glutamine, and 10% FBS. cFB 
conditioned media was collected every 2 d from cFBs while they were 
grown until confluence, at which point the media across the entire 
culture time was combined and homogenized.
Bioink Preparation: GelMA solutions of 14.432% were created by 
dissolving lyophilized GelMA in 15 × 10−3 m HEPES buffer and allowed 
to dissolve under stirring at 60 °C for 1–2 h. GelMA solutions were 
frozen at −20 °C until use. Stock solutions of 13 mg mL−1 cECM were 
formed by rehydrating the cECM material with HEPES buffer followed 
by adjusting the solution to pH 7.4 with HCl immediately prior to use. 
All bioinks were prepared immediately before printing. GelMA bioinks 
were prepared by mixing GelMA (final concentration 5% w/v), Eosin 
Y (100 × 10−6 m), NVP (0.75% v/v), TEOA (3% v/v), and HEPES buffer 
(15 × 10−3 m). In the case of GelMA-cECM bioinks, the HEPES in the 
above formulation was replaced by the cECM (final concentration 
8 mg mL−1) solutions. For the inclusion of cells, neonatal hCPCs 
(passage 6–10) were removed from cell culture plates, pelleted at 
1000 rpm for 5 min, and mixed with 1 mL solution of the bioink solution, 
producing a final concentration of 3 million cells mL−1.
Bioprinting and Patch Formation: All bioink solutions, with or 
without cells, underwent similar printing protocols. 1 mL of bioink was 
deposited into sterilized 30 cc printer barrels and pushed toward the 
barrel head with a sterile loose fit plunger, removing any air bubbles that 
formed. A sterile 27-guage plastic needle tip was added to the barrel, 
and a cap connecting the print head to the barrel as added. The barrels 
were put in the low-temperature head of the bioprinter (EnvisionTEC 
3D-bioplotter Developer Series), which was set to 10 °C, and the bioink 
Adv. Healthcare Mater. 2018, 7, 1800672
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was allowed to polymerize for 10 min. After initial gelation, the printer 
head was calibrated and purged at 1.2 bar for 1–3 s to ensure free 
flowing and uniform filaments. Patches and grids were printed onto a 
glass slide platform at room temperature, using a pressure 0.7–0.8 bar 
and speed of 10 mm s−1. Patches were 10 mm in diameter and 0.6 µm 
thick, which printed in three layers, with an infill pattern of 90° grids 
with 0.5 mm spacing. Six patches were printed at once. Test grids were 
10 mm × 10 mm boxes with an infill pattern of 90° grids with 1 mm 
spacing. CAD models of the patches and grids printed were generated 
using SOLIDWORKS and imported to the printing control system 
through the Bioplotter RP program. Following printing, both patches 
and test grids were exposed to white light (Braintree Scientific) at 4 °C 
for 5 min to allow for radical polymerization. The patches were removed 
from glass slides and put in 2 mL solutions of cell culture media in 
24-well plates. Patches that were being evaluated for paracrine release 
were put in 2 mL solutions of treatment media in 24-well plates. The 
treatment media consisted of Hams F-12 media supplemented with 
1 × Pen-Strep, 1% l-glutamine, 1 × ITS, and 10 ng mL−1 bFGF. All 
patches were kept in cell culture incubators during further experiments, 
which allowed for cECM polymerization within 1 h after GelMA radical 
polymerization. Media was changed and/or harvested every 2 d for each 
group. The test grids followed a similar protocol after polymerization, 
with the difference being that the grids were not removed from the 
slides and media was added directly over the grids to allow for full and 
complete coverage. The test grids were left in the cell culture incubator 
for 1 h to allow for the cECM to fully polymerize, washed several times, 
and removed immediately for imaging.
Imaging Printed Test Grids: Imaging of the printed test grids was 
performed at 10× magnification with an Olympus 1 × 71 Inverted 
Microscope. Bright-field images of both GelMA and GelMA-cECM 
grids were taken for printability comparison. For evaluating cECM 
homogeneity throughout the printed structures, cECM solutions were 
allowed to bind with AF568 at 4 °C for 1 h, which forms a strong bond to 
primary amines, at a concentration of 13.3 µg mL−1 based on modifying 
a previously described protocol.[60] The cECM solution was used to form 
test grids as described in the printing section, followed by swelling and 
incubation for at least 1 h at 37 °C. Stained GelMA-cECM test grids 
were imaged at 10× magnification both on an Olympus 1 × 71 Inverted 
Microscope and Olympus FV1000 Confocal Microscope. Printed 
test grids with hCPCs were also imaged at 10× magnification with an 
Olympus 1 × 71 Inverted Microscope. To image only cells, hCPCs were 
incubated with the lyophilic dye DiD according to manufacture protocol. 
Briefly, hCPCs were trypsinized from cell culture dishes, counted, and 
pelleted. The cells were suspended at a density of 1 million cells mL−1 in 
serum-free culture media supplemented with 5 µL mL−1 of DiD solution 
(1 mg mL−1 stock) and mixed. hCPCs were allowed to incubate for 
20 min at 37 °C. The cells were centrifuged at 1000 rpm for 5 min, the 
supernatant was removed, and the cells were resuspended in serum-free 
media. The wash procedure was repeated twice to remove any unbound 
DiD, and the cells were resuspended in the bioink solution for printing 
as described above. Printed test grids were again imaged at 10× on 
the fluorescence microscope. For image analysis of cell homogeneity 
throughout the printed structure, ImageJ was used to measure several 
line scans of fluorescence intensity along grid lines, which were then 
averaged to produce the figure.
Printability Analysis: The printability analysis implemented in this 
work looks at the effectiveness of the extruded filaments in the test grids 
to form square holes between filaments, as previously described.[41] 
Circularity (C) of an enclosed area is based on the shape perimeter and 
area, where a perfect circle has a circularity of 1. For a square shape, 
circularity is equal to π/4. To this end, and as previously derived and 













where L is perimeter and A is area of a shape. A printability of 1 is equal 
to a perfect square, and indicates optimal gelation, and thus printing, 
conditions of a bioink. Bright-field images of test grids were evaluated by 
measuring the perimeter and area of several holes in each sample and 
Pr was calculated using Equation (1), with three technical replicates and 
4–6 holes per n.
Rheological Analysis: As the printed patches were too thick to be 
measured on a rheometer without rupture, disk-shaped hydrogels 
without cells were made by sandwiching 15 µL of sample solution 
between two glass slides separated by a thin spacer, allowed to gel at 
4 °C for 10 min, and polymerized by white light (Braintree Scientific) 
for 5 min at 4 °C. The sample disks were incubated overnight in cell 
treatment media to undergo cECM polymerization and swelling. The 
storage and loss moduli of the disks were measured using dynamic 
oscillatory strain and frequency sweeps performed on an Anton 
Paar MCR 302 stress-controlled rheometer with a 9 mm diameter 
2° measuring cone.[61] The disks were loaded in the rheometer and 
the system was lowered to a 39 µm gap. Strain amplitude sweeps were 
performed at ω = 10 rad s−1 to determine the linear viscoelastic range of 
the samples. Oscillatory frequency sweeps between 0.5 and 30 rad s−1 
and 2% strain were then used to measure the storage and loss moduli. 
Samples were measured at 1, 4, 7, 12, and 21 d for degradation analysis 
of cell-free samples grown in treatment media and at 1, 7, and 21 d for 
degradation analysis of cell-laden samples grown in cFB conditioned 
media. All samples had 3–6 technical replicates per n.
Swelling: Patches were printed without cells as described above and 
allowed to swell for 24 h in treatment media. The swollen patches were 
weighed (wet weight) and put in separate centrifuge tubes. The samples 
were lyophilized in a Labconvo lyophilizer for 2 d and the weight of 
the dried material was measured (dry weight). All samples had three 
technical replicates per n. Swelling ratio was calculated as wet weight/
dry weight.
Degradation: Patches were printed as described above and allowed to 
swell for at least 24 h in treatment media. For measuring of degradation 
via weight change, the patches were weighed at days 1, 3, 7, 10, 15, and 
21 after formation, and degradation via hydrolysis was determined as 
change in weight compared to original weight at day 1. For measurement 
of degradation via mechanics, as described in the Rheological Analysis 
section, mechanical measurements of the materials were taken at 
1, 4, 7, 12, and 21 d for cell-free samples grown in treatment media, 
and at 1, 7, and 21 d for cell-laden samples grown in cFB conditioned 
media. Degradation was determined as the change in storage modulus 
(measured at 1.61 rad s−1) compared to original modulus at day 1. All 
samples had 3–6 technical replicates per n.
Viability Analysis: hCPC containing patches were grown in cell culture 
media for 1, 3, or 6 d, changing media every 2 d. Patches were removed 
from growth plates and placed in a 250 µL solution of 3 µL mL−1 
Calcein AM (live) and 2 µL mL−1 EtD (dead) in HBSS in 48-well plates. 
The patches were left for 30 min at 37 °C to incubate, followed by two 
washing with 1× HBSS for 5 min each. The patches were removed and 
placed on glass bottom dishes for imaging on an Olympus FV1000 
Confocal Microscope. Live/dead images of the hCPCs within the patches 
were taken at several locations. Several areas of each patch, six patches 
each, were used as technical replicates to evaluate data expressed as live 
cells/total cells.
Tube Formation Assay: Conditioned media from empty or hCPC 
containing patches were grown in treatment media and collected at days 
3 and 7. The conditioned media was centrifuged at 10 000 g for 10 min 
to remove any cell debris or particulate matter, and the supernatant was 
stored at −80 °C until analysis. HUVECs were grown on 0.1% w/v gelatin-
coated T-75 tissue culture plates with endothelial cell growth media until 
assays were performed. Tube formation assays were implemented as 
previously described.[59,62] In short, HUVECs were removed from culture 
using trypsin and added to Matrigel-coated well plates at a concentration 
of 10 000 cells/well. Conditioned media harvested from patches (200 µL) 
was added to the top of each well. For positive controls, nonconditioned 
treatment media was added. All HUVECs were allowed to grow for 6 h. 
Calcein AM dye (2 mg mL−1) was added to each well and cells were 
imaged via fluorescence to measure tube formation. Extent of total tube 
length formed in each well was evaluated by the Angiogenesis Analyzer 
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for ImageJ (Gilles Carpentier), and the total tube length for each sample 
was normalized to the value of the positive controls.
RNA Isolation, Reverse Transcription, and Quantitative Real-Time 
PCR: Cell-laden patches were grown in culture media for 3 and 7 d. At 
each time point, three technical replicates/n were harvested, added to 
vials containing 1 mL Trizol to isolate RNA, and homogenized (Fisher 
Scientific PowerGen 500) for several minutes.[61] The homogenized 
suspension was centrifuged at 15 000 g for 1 min with QIAshredder filters 
to separate the cellular components from the gel. RNA extraction was 
performed according to manufacturer’s protocols. RNA quantification 
and purity were determined by measuring absorbance at 260 and 280 nm 
wavelength on a spectrophotometer (Thermo Scientific NanoDrop One), 
followed by running reverse transcription as previously described.[16,17,61] 
Briefly, 0.5–2 µg RNA was mixed with hexamers, oligo(dT), dNTP, and 
RNase-free water in a final volume of 12 µL, and samples were heated 
to 65 °C for 5 min to denature the RNA, followed by cooling to 25 °C for 
10 min to allow for components to anneal. Then, RNaseOUT inhibitor, 
M-MLV, first strand buffer, and dithiothreitol were added to solutions, 
heated to 37 °C for 60 min to undergo reverse transcription, and 70 °C 
for 15 min for enzyme inactivation. cDNA samples were stored at −80 °C 
prior to further measurement. Gene expression was measured using a 
quantitative real-time PCR system (Applied Biosystems, StepOne Plus 
Software). cDNA in 1:5 ratio was mixed with Power SYBER Green, 
RNase-free water, and target primer, heated to 95 °C for 10 min, and 
allowed to run for 40 cycles, as previously described.[16,17] Each sample 
was run in triplicate per primer, and ΔΔCt method was used to obtain 
fold change values over GAPDH and GelMA control.[59] The primer 
sequences used are seen in Table 1.
Proliferation: Cell-laden patches were grown in culture media 
supplemented with 20 × 10−6 m EdU for 3 and 7 d. At each time point, 
patches were harvested and cut into equal size sections to fit in 96-well 
plates. Click-iT EdU assay was performed according to manufacturer’s 
instructions. Briefly, cell-laden samples were fixed and incubated with 
Click-iT reaction cocktail. Samples were then incubated with anti-Oregon 
green HRP, followed by incubation in Amplex UltraRed reaction mixture. 
The reaction was stopped after 15 min, absorbance of each well was 
measured, and absorbance of the blank was subtracted from each 
sample. Absorbance from GelMA-cECM patches was normalized to the 
absorbance of GelMA patches for each n.
Rat Surgery and Imaging: All animal experiments were performed 
with the approval of the Institutional Animal Care and Use Committee 
of Emory University. GelMA-cECM patches used for in vivo experiments 
were created in the same way as described in the Bioprinting section, 
with the difference being that AF568 dye was allowed to bind to cECM 
before patch formation, similar to the methodology described in the 
Imaging Printed Test Grids section. Sprague-Dawley Rats (≈250 g in 
weight) were anesthetized with 2% isoflurane, intubated, and placed 
on the ventilator (Hallowell Emc Microvent 1). Following thoracotomy, 
the pericardial sac was then very carefully exposed and pulled back. 
The patch was then gently placed over the right ventricle of the heart, 
ensuring that there was no folding of the patch. Patches were left without 
further attachment, tucked underneath the pericardium, or attached the 
ventricle using a single suture. After 7 and 14 d, rats were sacrificed and 
hearts were excised. Hearts were imaged using an Odyssey CLx (Li-Cor) 
for both patch fluorescence and heart background fluorescence, with an 
acquisition area of 20.07 mm × 20.07 mm.
Immunohistological Analysis: Excised hearts were fixed with 4% PFA, 
sectioned, and mounted onto coverslips. Tissue sections were incubated 
overnight with IsolectinB4-FITC in blocking buffer (3% BSA, 0.1% Triton 
X-100, 1× PBS) at 4 °C. Sections were then incubated with DAPI and 
mounted. Tissue sections were imaged on an Olympus FV1000 Confocal 
Microscope.
Statistics: Numerical data are the mean ± SEM. All data except for 
printability were analyzed using one-way ANOVAs with Tukey’s multiple 
comparison post-test. Sample size (n) was 3–6 for all samples. In cases 
where both days and groups were involved, data were compared across 
groups within the same day and across days within the same group 
to determine significant differences. An unpaired t-test was used to 
compare GelMA and GelMA-cECM in the printability analysis.
Supporting Information
Supporting Information is available from the Wiley Online Library or 
from the author.
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